What is Matinas BioPharma Holdings, Inc.'s earnings per share (EPS)?

Matinas BioPharma Holdings, Inc. (MTNB) reported diluted earnings per share of -$2.00 for fiscal year 2025. This represents a 59.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Matinas BioPharma Holdings, Inc. (MTNB) Financials

MTNB

FY2025 annual

Revenue Not reported for FY2025

Net Income -$10.3M +57.3% YoY

EPS (Diluted) -$2.00 +59.8% YoY

Operating Cash Flow -$7.0M +55.9% YoY

Market Cap $2.7M as of Oct 13, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 1.5x on $1.8M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 13, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 13, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MTNB SEC filings page.

This page shows Matinas BioPharma Holdings, Inc. (MTNB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI MTNB FY2025 2026-10-03

Development spending and cash losses contracted sharply in FY2025, but operations still depended on outside financing rather than internally generated cash.

The FY2025 operating loss fell to $6.96M from $24.6M, while operating cash flow was -$7.01M; the close match suggests the reported losses were largely cash costs rather than accounting charges.

The improvement is not explained by a margin story: usable revenue and gross-margin data stop before FY2024, while research spending fell from $11.4M in FY2024 to $85K in FY2025. That points to sharply reduced development spending alongside lower losses, not demonstrated commercial scale.

The balance sheet contracted materially, with assets falling from $12.6M to $7.2M and liabilities from $5.1M to $2.4M between FY2024 and FY2025. Reported liquidity equaled 6.8 months of FY2025 operating outflow, while financing supplied $3.39M against operating cash flow of -$7.01M, showing that cash needs were still externally supported.

Financial Health Signals

Financial health score not available

Matinas BioPharma Holdings, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

2/6

Matinas BioPharma Holdings, Inc. passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality No Cash Backing

N/A

Matinas BioPharma Holdings, Inc. reported a net loss of $10.3M while operations used $7.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$1.6M

YoY+14.8%

QoQ+19.7%

Matinas BioPharma Holdings, Inc.'s EBITDA was -$1.6M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 14.8% from the same quarter a year earlier. Against the prior quarter it is up 19.7%.

Net Income

-$1.3M

YoY+74.7%

QoQ+31.0%

Matinas BioPharma Holdings, Inc. reported -$1.3M in net income in Q2 2026. This represents an increase of 74.7% from the same quarter a year earlier. Against the prior quarter it is up 31.0%.

EPS (Diluted)

-$0.21

Matinas BioPharma Holdings, Inc. earned -$0.21 per diluted share (EPS) in Q2 2026.

Revenue

Not reported for Q2 2026.

Cash & Balance Sheet

Cash & Debt

$761K

YoY-88.3%

QoQ-68.3%

5Y CAGR-52.2%

10Y CAGR+2.8%

Matinas BioPharma Holdings, Inc. held $761K in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

15M

5Y CAGR-41.5%

10Y CAGR-12.8%

Matinas BioPharma Holdings, Inc. had 15M shares outstanding in Q2 2026.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-73.7%

YoY-5.3pp

QoQ-10.1pp

Matinas BioPharma Holdings, Inc.'s ROE was -73.7% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 5.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 10.1 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

None of these metrics is reported for Q2 2026.

MTNB Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MTNB quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Revenue	N/A	N/A	N/A	$1.1M-65.6%	$3.2M+9560.6%	$33K-79.2%	$158K+76.3%	$90K-25.0%	$120K-20.0%	$150K	$0-100.0%	$194K	$0	N/A
R&D Expenses	N/A	$85K-99.3%	$11.4M-21.1%	$14.5M-13.1%	$16.7M+14.4%	$14.6M+1.6%	$14.4M+27.8%	$11.2M+65.5%	$6.8M-24.7%	$9.0M+128.3%	$3.9M-25.4%	$5.3M+2.3%	$5.2M+193.8%	$1.8M
SG&A Expenses	N/A	$6.9M-21.2%	$8.7M-15.8%	$10.4M-6.5%	$11.1M+9.0%	$10.2M+1.8%	$10.0M+28.7%	$7.8M-2.5%	$8.0M+4.4%	$7.6M+77.3%	$4.3M-10.5%	$4.8M-9.0%	$5.3M+171.1%	$2.0M
Operating Income	N/A	-$7.0M+71.7%	-$24.6M-3.5%	-$23.8M+3.4%	-$24.6M+0.6%	-$24.7M-2.2%	-$24.2M-27.9%	-$18.9M-29.2%	-$14.6M+11.2%	-$16.5M-99.9%	-$8.3M+16.7%	-$9.9M+5.3%	-$10.5M-181.9%	-$3.7M
EBITDA	N/A	-$6.9M+71.4%	-$24.2M-3.6%	-$23.4M+3.6%	-$24.3M+1.0%	-$24.5M-2.2%	-$24.0M-28.1%	-$18.7M-29.7%	-$14.4M+12.0%	-$16.4M-99.9%	-$8.2M+16.9%	-$9.9M+5.3%	-$10.4M-180.9%	-$3.7M
Income Tax	N/A	N/A	-$80K	N/A	N/A	N/A	N/A	N/A	$507K+26.7%	$400K	N/A	N/A	$270K	N/A
Net Income	N/A	-$10.3M+57.3%	-$24.3M-5.7%	-$22.9M-9.3%	-$21.0M+9.8%	-$23.3M-3.7%	-$22.4M-29.2%	-$17.4M-23.4%	-$14.1M+9.1%	-$15.5M-103.8%	-$7.6M+16.8%	-$9.1M+10.6%	-$10.2M-175.3%	-$3.7M
EPS (Basic)	N/A	-$2.00+59.8%	-$4.98+5.7%	-$5.28-5180.0%	-$0.10+9.1%	-$0.11	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	—	-$2.00+59.8%	-$4.98	-$5.28	-$0.10	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	5M+12.5%	5M	4M	217M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
R&D Expenses	N/A	N/A	N/A	N/A	N/A	$85K-97.5%	N/A	$2.2M-32.0%
SG&A Expenses	$1.6M-15.4%	$1.9M+4.0%	N/A	$1.6M-26.4%	$1.8M-25.6%	$1.9M-24.2%	N/A	$2.1M-24.6%
Operating Income	-$1.6M+15.4%	-$1.9M+0.5%	N/A	-$1.6M+64.0%	-$1.8M+68.5%	-$1.9M+67.0%	N/A	-$4.4M+28.6%
EBITDA	-$1.6M+14.8%	-$1.9M-0.4%	N/A	-$1.6M+63.3%	-$1.8M+68.3%	-$1.9M+66.8%	N/A	-$4.3M+28.9%
Net Income	-$1.3M+74.7%	-$1.9M-16.0%	N/A	-$1.5M+64.2%	-$5.2M+8.3%	-$1.7M+71.6%	N/A	-$4.3M+29.4%
EPS (Basic)	-$0.21+79.6%	-$0.30+9.1%	-$0.26+84.5%	-$0.40+52.9%	-$1.03+10.4%	-$0.33+75.4%	-$1.68-5500.0%	-$0.85+38.8%
EPS (Diluted)	-$0.21	-$0.30+9.1%	-$0.26+84.5%	-$0.40+52.9%	-$1.03	-$0.33	-$1.68	-$0.85
Diluted Shares (Avg)	6M	6M+25.9%	N/A	5M+7.9%	5M	5M	N/A	5M

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense, Income Tax.

MTNB Balance Sheet

MTNB quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Total Assets	$7.2M-43.0%	$12.6M-49.6%	$25.1M-44.0%	$44.8M-26.9%	$61.3M-13.6%	$71.0M+76.4%	$40.2M+101.8%	$19.9M+38.3%	$14.4M+46.9%	$9.8M+16.8%	$8.4M+150.1%	$3.4M-70.3%	$11.3M
Current Assets	$4.1M-49.2%	$8.0M-48.4%	$15.5M-55.0%	$34.5M-32.3%	$51.0M-17.2%	$61.6M+105.7%	$29.9M+128.7%	$13.1M+64.3%	$8.0M+74.4%	$4.6M+28.3%	$3.6M+26.9%	$2.8M-74.3%	$10.9M
Cash & Equivalents	$4.0M-45.1%	$7.3M+52.2%	$4.8M-29.9%	$6.8M-67.5%	$21.0M+69.2%	$12.4M-43.9%	$22.2M+78.1%	$12.4M+70.3%	$7.3M+78.0%	$4.1M+27.2%	$3.2M+24.6%	$2.6M-76.1%	$10.8M
Short-Term Investments	$0	$0-100.0%	$9.0M-59.1%	$21.9M-23.3%	$28.6M-38.2%	$46.2M+725.1%	$5.6M	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0-100.0%	$536K-0.9%	$541K+368.8%	$115K-46.7%	$216K-31.5%	$316K
Goodwill	N/A	N/A	$1.3M0.0%	$1.3M0.0%	$1.3M0.0%	$1.3M0.0%	$1.3M0.0%	$1.3M0.0%	$1.3M0.0%	$1.3M0.0%	$1.3M	$0	N/A
Total Liabilities	$2.4M-52.9%	$5.1M-13.8%	$5.9M-28.4%	$8.2M-7.4%	$8.8M+22.0%	$7.2M+0.7%	$7.2M+89.1%	$3.8M+1.6%	$3.7M+40.3%	$2.7M+14.3%	$2.3M+105.9%	$1.1M+32.0%	$859K
Current Liabilities	$1.5M-45.1%	$2.7M+1.7%	$2.6M-38.8%	$4.3M-1.4%	$4.3M+21.9%	$3.6M+15.2%	$3.1M+9.1%	$2.8M+60.5%	$1.8M+22.5%	$1.4M+28.0%	$1.1M+0.9%	$1.1M+30.2%	$859K
Non-Current Liabilities	$915K-61.6%	$2.4M-26.3%	$3.2M-16.9%	$3.9M-13.1%	$4.5M+22.2%	$3.7M-10.3%	$4.1M+325.5%	$962K-51.3%	$2.0M+61.5%	$1.2M+1.4%	$1.2M+7781.4%	$15K	$0
Total Equity	$4.8M-36.4%	$7.6M-60.6%	$19.2M-47.5%	$36.6M-30.2%	$52.5M-17.6%	$63.7M+92.8%	$33.1M+104.8%	$16.1M+51.1%	$10.7M+49.4%	$7.1M+17.7%	$6.1M+172.6%	$2.2M-78.7%	$10.5M
Retained Earnings	-$210.8M-5.5%	-$199.8M-13.8%	-$175.6M-15.0%	-$152.6M-16.0%	-$131.6M-22.4%	-$107.5M-27.4%	-$84.4M-28.0%	-$65.9M-28.6%	-$51.3M-45.8%	-$35.2M-51.7%	-$23.2M-65.0%	-$14.1M-266.8%	-$3.8M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$3.4M-70.1%	$5.9M-51.2%	$7.2M-43.0%	$9.7M-52.9%	$11.4M-53.1%	$12.0M-38.6%	$12.6M-49.6%	$20.6M-30.9%
Current Assets	$1.1M-84.3%	$2.8M-62.7%	$4.1M-49.2%	$5.7M-51.9%	$7.3M-52.5%	$7.5M-26.6%	$8.0M-48.4%	$11.7M-41.3%
Cash & Equivalents	$761K-88.3%	$2.4M-65.4%	$4.0M-45.1%	$5.4M-47.2%	$6.5M+54.8%	$6.9M+546.5%	$7.3M+52.2%	$10.3M+60.7%
Short-Term Investments	$0	$0	$0	$0-100.0%	$0-100.0%	$0-100.0%	$0-100.0%	$500K-95.8%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$1.3M0.0%
Total Liabilities	$1.6M-57.0%	$2.9M-50.5%	$2.4M-52.9%	$3.2M-32.6%	$3.7M-28.8%	$5.8M+14.1%	$5.1M-13.8%	$4.8M-27.8%
Current Liabilities	$1.4M-24.3%	$2.1M-5.7%	$1.5M-45.1%	$1.5M-29.6%	$1.8M-25.4%	$2.3M+12.9%	$2.7M+1.7%	$2.1M-34.2%
Non-Current Liabilities	$262K-86.7%	$726K-79.3%	$915K-61.6%	$1.7M-34.9%	$2.0M-31.5%	$3.5M+14.9%	$2.4M-26.3%	$2.7M-21.6%
Total Equity	$1.8M-76.5%	$3.0M-51.8%	$4.8M-36.4%	$6.5M-59.1%	$7.7M-59.8%	$6.3M-56.9%	$7.6M-60.6%	$15.8M-31.8%
Retained Earnings	-$214.0M-3.5%	-$212.7M-5.6%	-$210.8M-5.5%	-$208.9M-9.1%	-$206.7M-10.5%	-$201.5M-11.1%	-$199.8M-13.8%	-$191.4M-12.4%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Long-Term Debt.

MTNB Cash Flow Statement

MTNB quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Operating Cash Flow	-$6.4M	-$7.0M+55.9%	-$15.9M-4.0%	-$15.3M+20.2%	-$19.2M-25.8%	-$15.2M+12.3%	-$17.4M-23.2%	-$14.1M-36.5%	-$10.3M+9.9%	-$11.5M-87.3%	-$6.1M+21.7%	-$7.8M+1.8%	-$8.0M-166.5%	-$3.0M
Depreciation & Amortization	N/A	$32K-91.2%	$365K-5.2%	$385K+14.2%	$337K+38.1%	$244K+5.6%	$231K+12.2%	$206K-5.7%	$218K+117.0%	$101K+91.1%	$53K+21.0%	$44K+4.6%	$42K+3576.5%	$1K
Stock-Based Compensation	N/A	$1.0M-68.0%	$3.2M-35.4%	$4.9M-5.4%	$5.2M+21.8%	$4.3M-6.0%	$4.6M+52.9%	$3.0M-22.1%	$3.8M+6.5%	$3.6M+136.8%	$1.5M-4.6%	$1.6M-19.3%	$2.0M+506.1%	$326K
Capital Expenditures	N/A	N/A	N/A	$218K-75.6%	$892K+243.1%	$260K+4422.5%	$6K-98.6%	$406K-24.3%	$536K-43.1%	$942K	$0-100.0%	$76K-73.6%	$289K+206.3%	$94K
Free Cash Flow	N/A	N/A	N/A	-$15.5M+22.7%	-$20.0M-29.5%	-$15.5M+10.9%	-$17.4M-19.8%	-$14.5M-33.5%	-$10.9M+12.5%	-$12.4M-102.7%	-$6.1M+22.5%	-$7.9M+4.4%	-$8.2M-167.7%	-$3.1M
Investing Cash Flow	N/A	$335K-96.4%	$9.2M-30.5%	$13.2M+171.5%	$4.9M-70.9%	$16.8M+141.2%	-$40.7M-576.5%	-$6.0M-1021.7%	-$536K+43.1%	-$942K	N/A	-$5K	N/A	N/A
Financing Cash Flow	N/A	$3.4M-63.0%	$9.2M+131157.1%	-$7K-108.9%	$79K-98.9%	$7.0M-85.5%	$48.0M+61.0%	$29.9M+88.1%	$15.9M+1.7%	$15.6M+123.0%	$7.0M-17.3%	$8.5M	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$1.8M+9.2%	-$1.6M+20.2%	-$1.5M+57.0%	-$1.5M+57.9%	-$2.0M+34.9%	-$2.0M+65.2%	-$3.5M+23.3%	-$3.5M+20.8%
Depreciation & Amortization	$0-100.0%	$0-100.0%	$3K-96.7%	$2K-97.8%	$12K-86.7%	$18K-80.9%	$90K-7.2%	$90K-8.2%
Stock-Based Compensation	$104K-56.3%	$113K-64.1%	N/A	$253K-73.8%	$238K-76.0%	$315K-68.3%	N/A	$965K-19.3%
Investing Cash Flow	N/A	N/A	$15K-97.0%	N/A	N/A	N/A	$500K-83.1%	$9.6M+789.9%
Financing Cash Flow	N/A	N/A	$58K+5900.0%	$64K+195.5%	$1.6M-82.3%	$1.6M+3007.5%	-$1K0.0%	-$67K-6600.0%

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

MTNB Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MTNB quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Operating Margin	N/A	N/A	-2168.4%	-771.3%	-74954.5%	-15288.4%	-21067.4%	-12230.9%	-11024.6%	N/A	-5096.0%	N/A	N/A
Net Margin	N/A	N/A	-2093.3%	-658.6%	-70554.5%	-14177.0%	-19343.4%	-11760.4%	-10345.9%	N/A	-4697.0%	N/A	N/A
Return on Equity	-214.2%+105.3pp	-319.5%-200.3pp	-119.2%-61.9pp	-57.3%-13.0pp	-44.4%-9.1pp	-35.2%+17.3pp	-52.6%+34.7pp	-87.3%+57.7pp	-145.0%-38.7pp	-106.3%+44.2pp	-150.4%+308.3pp	-458.8%-423.3pp	-35.4%
Return on Assets	-143.5%+48.3pp	-191.8%-100.5pp	-91.4%-44.5pp	-46.9%-8.9pp	-38.0%-6.3pp	-31.6%+11.5pp	-43.2%+27.5pp	-70.6%+36.8pp	-107.4%-30.0pp	-77.4%+31.3pp	-108.7%+195.4pp	-304.1%-271.3pp	-32.8%
Current Ratio	2.79-0.2x	3.01-2.9x	5.93-2.1x	8.06-3.7x	11.73-5.5x	17.25+7.6x	9.66+5.1x	4.61+0.1x	4.50+1.3x	3.160.0x	3.15+0.6x	2.51-10.2x	12.72
Debt-to-Equity	0.49-0.2x	0.67+0.4x	0.30+0.1x	0.22+0.1x	0.17+0.1x	0.11-0.1x	0.220.0x	0.24-0.1x	0.350.0x	0.370.0x	0.38-0.1x	0.51+0.4x	0.08
Asset Turnover	N/A	N/A	0.040.0x	0.07+0.1x	0.000.0x	0.000.0x	0.000.0x	0.010.0x	0.010.0x	0.000.0x	0.020.0x	0.00	N/A
FCF Margin	N/A	N/A	-1413.9%	-628.9%	-46918.2%	-10972.8%	-16142.2%	-9066.5%	-8285.1%	N/A	-4057.0%	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Equity	-73.7%-5.3pp	-63.6%-37.2pp	N/A	-23.7%+3.4pp	-68.3%-38.4pp	-26.4%+13.6pp	N/A	-27.1%-0.9pp
Return on Assets	-38.9%+7.1pp	-32.7%-18.9pp	N/A	-15.8%+5.0pp	-45.9%-22.4pp	-13.8%+15.9pp	N/A	-20.8%-0.5pp
Current Ratio	0.85-3.2x	1.32-2.0x	2.79-0.2x	3.78-1.7x	4.07-2.3x	3.35-1.8x	3.01-2.9x	5.53-0.7x
Debt-to-Equity	0.90+0.4x	0.940.0x	0.49-0.2x	0.50+0.2x	0.49+0.2x	0.92+0.6x	0.67+0.4x	0.300.0x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Matinas BioPharma Holdings, Inc. MTNB	FY2025	N/A	-$10.3M	N/A	$2.7M	—
LYRA THERAPEUTICS INC LYRA	FY2025	$398K	-$28.9M	N/A	$2.3M	—
Bolt Biotherapeutics, Inc. BOLT	FY2025	$7.7M	-$33.4M	N/A	$8.2M	64/100
Processa Pharmaceuticals, Inc. PCSA	FY2025	N/A	$13.6M	N/A	$5.3M	—
Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock CYCCP	FY2025	$747K	$3.0M	N/A	$9.6M	—
Aprea Therapeutics, Inc. APRE	FY2025	N/A	-$12.6M	N/A	$7.5M	—

Where Matinas BioPharma Holdings, Inc. Ranks

Frequently Asked Questions

Is Matinas BioPharma Holdings, Inc. profitable?

No, Matinas BioPharma Holdings, Inc. (MTNB) reported a net income of -$10.3M in fiscal year 2025.

What is Matinas BioPharma Holdings, Inc.'s EBITDA?

Matinas BioPharma Holdings, Inc. (MTNB) had EBITDA of -$6.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Matinas BioPharma Holdings, Inc.'s return on equity (ROE)?

Matinas BioPharma Holdings, Inc. (MTNB) has a return on equity of -214.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Matinas BioPharma Holdings, Inc.'s operating cash flow?

Matinas BioPharma Holdings, Inc. (MTNB) recorded an outflow of $7.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Matinas BioPharma Holdings, Inc.'s total assets?

Matinas BioPharma Holdings, Inc. (MTNB) had $7.2M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Matinas BioPharma Holdings, Inc. spend on research and development?

Matinas BioPharma Holdings, Inc. (MTNB) invested $85K in research and development during fiscal year 2025.

How many shares does Matinas BioPharma Holdings, Inc. have outstanding?

Matinas BioPharma Holdings, Inc. (MTNB) had 6M shares outstanding as of fiscal year 2025.

What is Matinas BioPharma Holdings, Inc.'s current ratio?

Matinas BioPharma Holdings, Inc. (MTNB) had a current ratio of 2.79 as of fiscal year 2025, which is generally considered healthy.

What is Matinas BioPharma Holdings, Inc.'s debt-to-equity ratio?

Matinas BioPharma Holdings, Inc. (MTNB) had a debt-to-equity ratio of 0.49 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Matinas BioPharma Holdings, Inc.'s return on assets (ROA)?

Matinas BioPharma Holdings, Inc. (MTNB) had a return on assets of -143.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Matinas BioPharma Holdings, Inc.'s P/E ratio?

Matinas BioPharma Holdings, Inc. (MTNB) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $2.7M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Matinas BioPharma Holdings, Inc.'s price-to-sales ratio?

Matinas BioPharma Holdings, Inc. (MTNB) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $2.7M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Matinas BioPharma Holdings, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Matinas BioPharma Holdings, Inc. (MTNB) held $4.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $7.0M over that year. Dividing the one by the other, the reported balance equals about 7 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Matinas BioPharma Holdings, Inc.'s Piotroski F-Score?

Matinas BioPharma Holdings, Inc. (MTNB) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Matinas BioPharma Holdings, Inc.'s earnings high quality?

Matinas BioPharma Holdings, Inc. (MTNB) reported a net loss of $10.3M while operations used $7.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.